{
    "clinical_study": {
        "@rank": "56997", 
        "arm_group": [
            {
                "arm_group_label": "ISU302", 
                "arm_group_type": "Experimental", 
                "description": "15 U/kg I.V. injection"
            }, 
            {
                "arm_group_label": "ISU302 30 U/kg", 
                "arm_group_type": "Experimental", 
                "description": "Drug ISU302 I.V. injection"
            }, 
            {
                "arm_group_label": "ISU302 60 U/kg", 
                "arm_group_type": "Experimental", 
                "description": "Drug ISU302 I.V. injection"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "ISU302 Placebo I.V. injection"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of\n      single dosing study with three ascending dose cohorts of ISU302 in healthy subjects."
        }, 
        "brief_title": "A Study of the Tolerability, Safety, and Pharmacokinetics of ISU302 in Healthy Volunteers", 
        "completion_date": {
            "#text": "November 2010", 
            "@type": "Actual"
        }, 
        "condition": "Gaucher Disease", 
        "condition_browse": {
            "mesh_term": "Gaucher Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male volunteers, aged between \u2265 20 and \u2264 45 years old\n\n          -  Weight \u2265 50, with calculated body mass index of 17 and 25 kg/m2\n\n               -  BMI = (Weight [kg])/(height [m])2\n\n          -  Subject is informed of the investigational nature of this study and voluntarily\n             agrees to participate in this study and comply with the relevant instructions in\n             written\n\n          -  Considered ineligible through screening test (such as medical history, physical\n             examination, ECG, safety laboratory test) performed within 35 days prior to study\n             start (dosing of investigational products)\n\n        Exclusion Criteria:\n\n          -  With symptoms indicating acute diseases within 28 days prior to start of study\n             (dosing of investigational product)\n\n          -  History or presence of clinically significant and active cardiovascular, respiratory,\n             renal, endocrine, hematological, gastrointestinal, central nervous system,\n             psychiatric disorder, autoimmune disease, or malignant tumor\n\n          -  Any medical history that may affect drug absorption, distribution, metabolism and\n             excretion(e.g., inflammatory gastric disease, gastric or intestinal ulcer, hepatic or\n             renal disease)\n\n          -  With presence of clinically significant allergic disease (including mild allergic\n             rhinitis or allergic dermatitis which does not need medication)\n\n          -  With presence of clinically significant hypersensitivity to any drugs\n\n          -  With hemolytic anemia, anemia due to blood loss (Hb < 14g/dL and Hct <42%)\n\n          -  With the results of safety laboratory test\n\n               1. AST (Aspartate Transaminase) or ALT (Alanine Transaminase) > 1.5 times of upper\n                  normal limit\n\n               2. Total bilirubin > 1.5 times of upper normal limit\n\n          -  Subject who has immune deficiency or medication with immune suppressants\n\n          -  Participation in other clinical study within 60 days prior to start of study (dosing\n             of investigational products)\n\n          -  Use of any drugs, possibly affecting drug metabolizing enzymes, within 1 month prior\n             dosing, or any drugs, possibly affecting the results of clinical trial within 10 days\n             or use of drug was not passes 5 x half-life of drug\n\n          -  Donated whole blood within 60 days, or transfused within 20 days before the study\n\n          -  History of alcohol abuse (> 14 units/week) and the subject could not stop drinking\n             alcohol beverage during study period\n\n          -  Heavy smoker (>10 cigarettes/day) or the subject could not stop smoking during study\n             period\n\n          -  Unwillingness or inability to follow the procedures outlined in the protocol\n\n          -  Positive in pregnancy test in urine and unwilling to follow contraception during\n             study period and following 3 months (for female subjects)."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01881633", 
            "org_study_id": "ISU-002"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "ISU302", 
                    "ISU302 30 U/kg", 
                    "ISU302 60 U/kg"
                ], 
                "intervention_name": "ISU302", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "gaucher disease, imiglucerase, ISU302", 
        "lastchanged_date": "June 18, 2013", 
        "number_of_arms": "4", 
        "official_title": "A Dose Block-randomized, Double-blind, Placebo-controlled, Single Dosing, Dose-escalation Phase I Clinical Trial to Evaluate the Tolerability, Safety, and Pharmacokinetics of ISU302 in Healthy Volunteers", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Evaluation for safety data by treatment group/ Confirmative evaluation for serious adverse drug reaction/ Descriptive statistics (arithmetic mean and standard deviation) for quantitative analysis and evaluation of change from baseline/ Frequency counts for qualitative categorization of safety data\nParameters:\nAdverse events including subjective/objective symptoms\nPhysical examination\n12-lead ECG\nVital signs\nLocal tolerability test\nClinical laboratory test: Hematology, Coagulation, Blood Chemistry, Urinalysis\nImmunogenicity", 
            "measure": "Safety and tolerability", 
            "safety_issue": "No", 
            "time_frame": "From Screening to Day 5 post-dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01881633"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Pharmacokinetic Parameter assessment using non-compartmental analysis from the concentration-time data/ Summary of Pharmacokinetic parameters by treatment group using descriptive statistics/ Dose proportionality\nParameters: Cmax, AUCt, AUCinf, Tmax, t1/2, Clearance, Vd, MRTr", 
            "measure": "Pharmacokinetics", 
            "safety_issue": "No", 
            "time_frame": "Day1"
        }, 
        "source": "ISU Abxis Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ISU Abxis Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2010", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}